TY - JOUR
T1 - Reversion of immune tolerance in advanced malignancy
T2 - Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
AU - Pan, Ping Ying
AU - Wang, George X.
AU - Yin, Bingjiao
AU - Ozao, Junko
AU - Ku, Teresa
AU - Divino, Celia M.
AU - Chen, Shu Hsia
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Tumor growth induced a significant increase of myeloid-derived suppressor cells (MDSCs) in the tumor-bearing host. In our previous study, we showed that MDSCs induced tumor-specific T-cell tolerance and the development of T regulatory cells (Tregs). Tumor-derived factors have been implicated in the accumulation of MDSCs. We hypothesize that reduction of MDSC accumulation in tumor-bearing hosts, through the blockade of tumor factors, can prevent T-cell anergy and Treg development and thereby improve immune therapy for the treatment of advanced tumors. Several tumor-derived factors were identified by gene array analysis. Among the candidate factors, stem-cell factor (SCF) is expressed by various human and murine carcinomas and was selected for further study. Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. More importantly, blockade of SCF receptor (ckit)-SCF interaction by anti-ckit prevented tumor-specific T-cell anergy, Treg development, and tumor angiogenesis. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors. This information supports the notion that modulation of MDSC development may be required to achieve effective immune-enhancing therapy for the treatment of advanced tumors.
AB - Tumor growth induced a significant increase of myeloid-derived suppressor cells (MDSCs) in the tumor-bearing host. In our previous study, we showed that MDSCs induced tumor-specific T-cell tolerance and the development of T regulatory cells (Tregs). Tumor-derived factors have been implicated in the accumulation of MDSCs. We hypothesize that reduction of MDSC accumulation in tumor-bearing hosts, through the blockade of tumor factors, can prevent T-cell anergy and Treg development and thereby improve immune therapy for the treatment of advanced tumors. Several tumor-derived factors were identified by gene array analysis. Among the candidate factors, stem-cell factor (SCF) is expressed by various human and murine carcinomas and was selected for further study. Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. More importantly, blockade of SCF receptor (ckit)-SCF interaction by anti-ckit prevented tumor-specific T-cell anergy, Treg development, and tumor angiogenesis. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors. This information supports the notion that modulation of MDSC development may be required to achieve effective immune-enhancing therapy for the treatment of advanced tumors.
UR - http://www.scopus.com/inward/record.url?scp=38049181485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38049181485&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-04-086835
DO - 10.1182/blood-2007-04-086835
M3 - Article
C2 - 17885078
AN - SCOPUS:38049181485
SN - 0006-4971
VL - 111
SP - 219
EP - 228
JO - Blood
JF - Blood
IS - 1
ER -